Cargando…
Potential clinical biomarkers in rheumatoid arthritis with an omic approach
OBJECTIVE: To aid in the selection of the most suitable therapeutic option in patients with diagnosis of rheumatoid arthritis according to the phase of disease, through the review of articles that identify omics biological markers. METHODS: A systematic review in PubMed/Medline databases was perform...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165788/ https://www.ncbi.nlm.nih.gov/pubmed/34059137 http://dx.doi.org/10.1186/s13317-021-00152-6 |
_version_ | 1783701383488208896 |
---|---|
author | Puentes-Osorio, Yolima Amariles, Pedro Calleja, Miguel Ángel Merino, Vicente Díaz-Coronado, Juan Camilo Taborda, Daniel |
author_facet | Puentes-Osorio, Yolima Amariles, Pedro Calleja, Miguel Ángel Merino, Vicente Díaz-Coronado, Juan Camilo Taborda, Daniel |
author_sort | Puentes-Osorio, Yolima |
collection | PubMed |
description | OBJECTIVE: To aid in the selection of the most suitable therapeutic option in patients with diagnosis of rheumatoid arthritis according to the phase of disease, through the review of articles that identify omics biological markers. METHODS: A systematic review in PubMed/Medline databases was performed. We searched articles from August 2014 to September 2019, in English and Spanish, filtered by title and full text; and using the terms "Biomarkers" AND “Rheumatoid arthritis". RESULTS: This article supplies an exhaustive review from research of objective measurement, omics biomarkers and how disease activity appraise decrease unpredictability in treatment determinations, and finally, economic, and clinical outcomes of treatment options by biomarkers’ potential influence. A total of 122 articles were included. Only 92 met the established criteria for review purposes and 17 relevant references about the topic were included as well. Therefore, it was possible to identify 196 potential clinical biomarkers: 22 non-omics, 20 epigenomics, 33 genomics, 21 transcriptomics, 78 proteomics, 4 glycomics, 1 lipidomics and 17 metabolomics. CONCLUSION: A biomarker is a measurable indicator of some, biochemical, physiological, or morphological condition; evaluable at a molecular, biochemical, or cellular level. Biomarkers work as indicators of physiological or pathological processes, or as a result of a therapeutic management. In the last five years, new biomarkers have been identified, especially the omics, which are those that proceed from the investigation of genes (genomics), metabolites (metabolomics), and proteins (proteomics). These biomarkers contribute to the physician choosing the best therapeutic option in patients with rheumatoid arthritis. |
format | Online Article Text |
id | pubmed-8165788 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-81657882021-06-01 Potential clinical biomarkers in rheumatoid arthritis with an omic approach Puentes-Osorio, Yolima Amariles, Pedro Calleja, Miguel Ángel Merino, Vicente Díaz-Coronado, Juan Camilo Taborda, Daniel Auto Immun Highlights Review OBJECTIVE: To aid in the selection of the most suitable therapeutic option in patients with diagnosis of rheumatoid arthritis according to the phase of disease, through the review of articles that identify omics biological markers. METHODS: A systematic review in PubMed/Medline databases was performed. We searched articles from August 2014 to September 2019, in English and Spanish, filtered by title and full text; and using the terms "Biomarkers" AND “Rheumatoid arthritis". RESULTS: This article supplies an exhaustive review from research of objective measurement, omics biomarkers and how disease activity appraise decrease unpredictability in treatment determinations, and finally, economic, and clinical outcomes of treatment options by biomarkers’ potential influence. A total of 122 articles were included. Only 92 met the established criteria for review purposes and 17 relevant references about the topic were included as well. Therefore, it was possible to identify 196 potential clinical biomarkers: 22 non-omics, 20 epigenomics, 33 genomics, 21 transcriptomics, 78 proteomics, 4 glycomics, 1 lipidomics and 17 metabolomics. CONCLUSION: A biomarker is a measurable indicator of some, biochemical, physiological, or morphological condition; evaluable at a molecular, biochemical, or cellular level. Biomarkers work as indicators of physiological or pathological processes, or as a result of a therapeutic management. In the last five years, new biomarkers have been identified, especially the omics, which are those that proceed from the investigation of genes (genomics), metabolites (metabolomics), and proteins (proteomics). These biomarkers contribute to the physician choosing the best therapeutic option in patients with rheumatoid arthritis. BioMed Central 2021-05-31 /pmc/articles/PMC8165788/ /pubmed/34059137 http://dx.doi.org/10.1186/s13317-021-00152-6 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Review Puentes-Osorio, Yolima Amariles, Pedro Calleja, Miguel Ángel Merino, Vicente Díaz-Coronado, Juan Camilo Taborda, Daniel Potential clinical biomarkers in rheumatoid arthritis with an omic approach |
title | Potential clinical biomarkers in rheumatoid arthritis with an omic approach |
title_full | Potential clinical biomarkers in rheumatoid arthritis with an omic approach |
title_fullStr | Potential clinical biomarkers in rheumatoid arthritis with an omic approach |
title_full_unstemmed | Potential clinical biomarkers in rheumatoid arthritis with an omic approach |
title_short | Potential clinical biomarkers in rheumatoid arthritis with an omic approach |
title_sort | potential clinical biomarkers in rheumatoid arthritis with an omic approach |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8165788/ https://www.ncbi.nlm.nih.gov/pubmed/34059137 http://dx.doi.org/10.1186/s13317-021-00152-6 |
work_keys_str_mv | AT puentesosorioyolima potentialclinicalbiomarkersinrheumatoidarthritiswithanomicapproach AT amarilespedro potentialclinicalbiomarkersinrheumatoidarthritiswithanomicapproach AT callejamiguelangel potentialclinicalbiomarkersinrheumatoidarthritiswithanomicapproach AT merinovicente potentialclinicalbiomarkersinrheumatoidarthritiswithanomicapproach AT diazcoronadojuancamilo potentialclinicalbiomarkersinrheumatoidarthritiswithanomicapproach AT tabordadaniel potentialclinicalbiomarkersinrheumatoidarthritiswithanomicapproach |